Pfizer Licenses Nutrition 21’s Chromax In Patent Claim Settlement
This article was originally published in The Tan Sheet
The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.
You may also be interested in...
Nutrition 21 Revives Under Leadership Of Former Pharma Exec Satow
Michael Satow, formerly of JDS Pharmaceuticals, tries his hand in the nutritional ingredients space as CEO of Nutrition 21. In a recent interview, Satow discussed his initial impressions of the industry and what potential he sees in a portfolio that includes Chromax chromium picolinate.
Nutrition 21 Files For Bankruptcy, Hamstrung By Finished Product Detour
Ingredient developer Nutrition 21 filed for Chapter 11 bankruptcy protection and is soliciting bidders for its assets following an unsuccessful transition into the finished nutritional product space.
Perrigo’s Next CEO Has Long OTC Brands History
Patrick Lockwood-Taylor starts as president/CEO on 30 June, succeeding Murray Kessler as Perrigo awaits FDA decision on subsidiary HRA’s proposal for first US OTC sales of daily oral contraceptive. He’s moving from president of Bayer AG’s US business and regional president, consumer health North America.